about
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the pote...
Read More
2.25
0.23
(11.39%)
872.1K
XNAS Volume
XNAS 20 Aug, 2025 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Climb Bio Inc. Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..